Key Highlights
- Shares of Aethlon Medical skyrocketed more than 471% during premarket hours on September 17, 2026, following the announcement of a merger with North Immunology
- The transaction is structured as an all-stock merger that will result in a newly formed Nasdaq-listed entity named North Immunology, Inc., which will trade under ticker symbol NRTX
- Post-merger ownership will see North Immunology shareholders and PIPE participants controlling approximately 95% of the combined enterprise, while Aethlon stockholders will retain about 4.75%
- The transaction includes a $180 million concurrent private placement supported by prominent healthcare investors such as Bain Capital Life Sciences and Janus Henderson, providing runway through late 2028
- The company’s flagship therapeutic candidate, NOR-101, a bispecific antibody targeting atopic dermatitis, is scheduled to begin Phase 1a clinical trials in early 2027
Shares of Aethlon Medical (AEMD) surged dramatically by over 471% during Thursday’s premarket session following the disclosure of a definitive merger agreement with North Immunology, a private biotechnology firm.
The transaction, publicly disclosed on September 17, 2026, structures the combination through two wholly owned merger subsidiaries: Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC.
Following completion of the merger, the combined organization will operate under the name North Immunology, Inc. and will maintain its listing on the Nasdaq Capital Market with the ticker symbol NRTX.
The merger agreement stipulates that North Immunology’s current shareholders, together with investors participating in the concurrent financing, will collectively control approximately 95.25% of the post-merger entity.
Meanwhile, current Aethlon stockholders will retain approximately 4.75% ownership in the new company, in addition to receiving contingent value rights connected to potential future monetization of Aethlon’s existing Hemopurifier technology platform.
Accompanying the merger announcement, the companies disclosed an oversubscribed $180 million private investment in public equity (PIPE) financing, indicating robust institutional interest in the transaction.
The financing syndicate comprises several prominent healthcare-focused investment firms, including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, Sirenia Capital Management LP, Farallon Capital Management, Adage Capital Partners LP, and TCGX.
The $180 million financing figure incorporates the conversion of roughly $34 million in existing convertible promissory notes held by North Immunology, including accumulated interest, premiums, and associated fees.
Management projects that the capital raised will adequately support the combined company’s operational requirements through the latter half of 2028.
North Immunology’s Development Pipeline
North Immunology specializes in developing bispecific antibody therapeutics that modulate inflammatory signaling pathways associated with immune-mediated conditions.
The company’s most advanced program, NOR-101, represents a half-life extended bispecific antibody that simultaneously targets IL-13 and IL-18, with primary development focused on treating atopic dermatitis.
Development Milestones for NOR-101
The initial Phase 1a clinical trial evaluating NOR-101 is slated to commence during the first quarter of 2027, with preliminary pharmacokinetic and safety results anticipated by mid-2027.
Management has indicated intentions to launch both Phase 1b and Phase 2b studies examining NOR-101 in atopic dermatitis patients throughout 2027.
Primary efficacy and safety data from these expansion studies are projected to become available in 2028.
The merger transaction is anticipated to reach completion during the first quarter of 2027, subject to obtaining necessary shareholder votes, regulatory clearances, and stock exchange approval.
Upon closing, North Immunology’s current executive leadership team and board of directors will assume control of the merged organization.
The latest analyst consensus rating on AEMD stock stands at Hold, with a price target of $1.50, based on TipRanks data.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
